Juliano R, Bauman J, Kang H, Ming X
UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Mol Pharm. 2009 May-Jun;6(3):686-95. doi: 10.1021/mp900093r.
Attaining the full therapeutic utility of antisense and siRNA oligonucleotides will require understanding of the biological barriers that stand between initial administration of these drugs and their final actions within cells. This review examines some of the key barriers that affect the biodistribution of oligonucleotides both in molecular form and when they are associated with nanocarriers. An understanding of the biological processes underlying these barriers will aid in the design of more effective delivery systems.
要实现反义寡核苷酸和小干扰RNA寡核苷酸的全部治疗效用，需要了解这些药物初始给药与它们在细胞内的最终作用之间存在的生物屏障。本综述探讨了一些影响寡核苷酸分子形式及其与纳米载体结合时生物分布的关键屏障。了解这些屏障背后的生物学过程将有助于设计更有效的递送系统。
